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Abstract:  Genetic recombination in RNA viruses was discovered many years ago for 
poliovirus (PV), an enterovirus of the Picornaviridae family, and studied using PV or other 
picornaviruses as models. Recently, recombination was shown to be a general phenomenon 
between different types of enteroviruses of the same species. In particular, the interest for 
this mechanism of genetic plasticity was renewed with the emergence of pathogenic 
recombinant circulating vaccine-derived polioviruses (cVDPVs), which were implicated in 
poliomyelitis outbreaks in several regions of the world with insufficient vaccination 
coverage. Most of these cVDPVs had mosaic genomes constituted of mutated poliovaccine 
capsid sequences and part or all of the non-structural sequences from other human 
enteroviruses of species C (HEV-C), in particular coxsackie A viruses. A study in 
Madagascar showed that recombinant cVDPVs had been co-circulating in a small 
population of children with many different HEV-C types. This viral ecosystem showed a 
surprising and extensive biodiversity associated to several types and recombinant 
genotypes, indicating that intertypic genetic recombination was not only a mechanism of 
evolution for HEV-C, but an usual mode of genetic plasticity shaping viral diversity. 
Results suggested that recombination may be, in conjunction with mutations, implicated in 
the phenotypic diversity of enterovirus strains and in the emergence of new pathogenic 
strains. Nevertheless, little is known about the rules and mechanisms which govern genetic 
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exchanges between HEV-C types, as well as about the importance of intertypic 
recombination in generating phenotypic variation. This review summarizes our current 
knowledge of the mechanisms of evolution of PV, in particular recombination events 
leading to the emergence of recombinant cVDPVs. 
Keywords: enterovirus; poliovirus; poliomyelitis; live vaccine; vaccine-derived poliovirus; 
VDPV; genetic plasticity; recombination; emergence 
 
1. Poliovirus and Poliomyelitis: Successes and Recent Hurdles in Eradication 
Recombination has been known to occur in the poliovirus (PV) genome for almost fifty years [1,2] 
and this virus has been used as a model to investigate recombination molecular mechanisms in single 
stranded RNA genomes of positive polarity. Recombination was first demonstrated between various 
strains of this virus that belongs to the Enterovirus genus in the Picornaviridae family. There are three 
stable serotypes of PV, determined by the viral capsid. Natural as well as engineered heterotypic 
recombinants have been reported. However, it has been only recently shown that the recombination of 
PV with other enteroviruses can be the source of new PV strain emergence [3].  
Picornaviruses are small viruses composed of a non-segmented positive strand RNA genome of 
about 7500 nucleotides (nt) surrounded by an icosahedral capsid composed of four proteins: VP1-4 
(Figure 1a). A single open-reading frame flanked by two non-coding regions (5'NC and 3'NC) 
characterize the viral genome (Figure 1b). Capsid proteins are encoded by the P1 genomic region and 
nonstructural proteins are encoded by P2-P3 regions. Viral replications cycles  are almost entirely 
cytoplasmic. HEVs constitute a large genus of viruses classified into four species of enteroviruses 
(HEV-A,  -B,  -C and -D) and three species of rhinoviruses.  PV is transmitted by the oral route, 
multiplies in the digestive tract, in the oropharynx and the intestine, and is excreted in stools for 
several weeks. Virus multiplication in the intestine is efficient but generally asymptomatic. From the 
digestive tract, PV reaches cervical and mesenteric lymph nodes and then establishes a viremia. Acute 
paralytic poliomyelitis caused by PV is associated with rare virus multiplication in motor neurons in 
the central nervous system (CNS), in the spinal cord, brainstem or motor cortex, in less than 1% of 
infections. It is generally admitted that PV enters the CNS by crossing the blood brain barrier during 
viremia, but a neuron-specific  pathway has also been reported [4,5]. Humoral immunity plays a 
predominant role in the prevention and cure of PV infection.  
The PV receptor (PVR) CD155 is a major determinant of PV tissue tropism, but the alpha/beta 
interferon also plays an important role in PV pathogenicity [6]. The interferon response limits PV 
movement from the periphery to the CNS [7]. Mice transgenic for the human PVR (Tg-PVR) were 
produced to create a convenient animal model that develops poliomyelitis following PV inoculation by 
various routes [8,9]. There is a very good correlation between the Tg-PVR murine and human disease 
in the CNS. However, these Tg-PVR mice are not a good model to mimic an oral infection by PV, and 
only the Tg-PVR mice that are deficient in alpha/beta interferon receptor are susceptible to oral 
infection by PV [10].  Viruses 2011, 3                         
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Figure 1. Schematic representation of the capsid and genome of poliovirus. (a) The 
icosahedral capsid of the virus is represented with the three external proteins VP1, -2 and  
-3 constituting a protomer. The 5-fold, 3-fold and 2-fold axis of symmetry are indicated. 
The canyon recognized by the cellular viral receptor CD155 is shown. (b) The genome is 
constituted of a poly-adenylated positive strand RNA genome that is covalently linked to a 
small viral protein VPg (also named 3B) at the 5' terminus. The single open-reading frame 
is flanked by two non-coding regions (5'NC and 3'NC). The single viral polyprotein is 
cleaved mostly by the viral proteases 2A, 3C and 3CD (triangles indicate cleavage sites). 
The peptidic precursors P1, P2 and P3 are subsequently cleaved to give the different viral 
proteins including the capsid proteins (VP1-4) and the non-structural proteins such as the 
RNA polymerase 3Dpol. 
 
 
In 1988, the World Health Organization (WHO) established a program to eradicate poliomyelitis, 
based on massive vaccination campaigns with the oral polio vaccine (OPV). This vaccine is composed 
of live attenuated viruses of the three serotypes (Sabin strains 1-3), able to multiply to high titers only 
in the gastrointestinal tract. The major genetic determinants involved in the attenuation of the three 
OPV strains are located in the 5'NC genomic regions and are known to affect the efficiency of the 
Internal Ribosomes Entry Site (IRES) and genomic translation, particularly in neuronal cells [3]. In 
addition, codons of capsid proteins are also implicated in attenuation. OPV is known to induce a strong 
intestinal immune response that limits both PV replication and circulation among humans. There is 
also an inactivated poliovaccine (IPV) prepared with wild-type strains of the three serotypes. Both 
vaccines are quite efficient to protect against disease. Nevertheless, IPV is less efficient than OPV for 
inducing the intestinal immunity. OPV is therefore the main tool of the Poliomyelitis Eradication 
Initiative launched and coordinated by the WHO.  Viruses 2011, 3                         
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Following 20 years of massive anti-polio immunization programs, poliomyelitis due to wild-type 
viruses is considerably less frequent worldwide and remains endemic in only four countries (India, 
Pakistan, Afghanistan and Nigeria): The estimated number of polio cases dropped from 350,000 in 
1988 to 715 in 2000 [11]. However, because of low vaccine coverage in some areas in countries of the 
developing world, the disease has not been eradicated. There were 1292 polio cases due to wild-type 
PV in 2010, indicating that there must have been more than 200,000 asymptomatic infected 
individuals. Low vaccine coverage over recent years has allowed occasional spread of wild PV strains 
from endemic countries to neighboring or distant countries where wild PV had disappeared [3]. In 
particular, there were some 600 cases of acute flaccid paralysis (AFP) and 458 cases of confirmed 
polio in Tajikistan and Uzbekistan in 2010, following the importation of PV from India. This 
constituted  the first importation of polio into the WHO European Region since it was certified 
polio-free in 2002. Still more recently, a severe outbreak of poliomyelitis occurred in the Democratic 
Republic of Congo with 383 confirmed polio cases and a very high mortality rate (42% instead of the 
usual 5–10% rate) [12]. 
Low vaccine coverage is also thought to allow circulation between humans, the genetic drift of 
OPV strains and the emergence of pathogenic, vaccine-derived polioviruses (VDPVs). These 
circulating VDPVs (cVDPVs) have recently caused iatrogenic epidemics of paralytic poliomyelitis in 
15 regions of the world, including Madagascar in 2002 and 2005 (see below Section 4 and Figure 2). 
Most cVDPVs are recombinants between PV and other HEV-C, principally coxsackie A viruses 
(CAV). All cVDPVs have similar genomic features: the region encoding the capsid proteins is from 
vaccine strains, but with more than 1% nt substitutions, and some or all of the rest of the genome, 
particularly the region encoding nonstructural proteins, originates from other HEV-C. Thus, cVDPVs 
greatly complicate the implementation of surveillance and vaccination strategies aimed at eradicating 
poliomyelitis and PV. In addition to public health issues, the emergence of cVDPVs by recombination 
reveals a fascinating mechanism of variability in HEV species. Analysis of this phenomenon should 
provide us with new insight into viral evolution.  
2. Poliovirus Evolution by Mutation and Recombination 
The underlying mechanisms of PV evolution are mutation, homologous and non-homologous 
recombination, followed in all cases by selection [13,14]. Many RNA viruses replicate near the error 
threshold. The high mutation rate of PV is in the order of 10
−4 errors per nt per replication cycle of the 
viral genome, due to the low fidelity of PV RNA polymerase 3D (3Dpol) and the absence of mismatch 
repair mechanism [15]. The 3Dpol error frequency was determined in vitro for at several sites in the 
viral genome, but there was no significant variation in the values [16]. However, the capsid-encoding 
region, with a rate of fixation of total substitutions in the order of 10
−2 substitutions/site/year, appears 
less genetically stable than the region encoding non-structural proteins [17,18].  
The pool of mutants differing by one or several mutations in a virus population is called 
quasispecies [19–21]. It has been proposed that viral populations, rather than individual variants, are 
the targets of evolutionary selection [22], and indeed, complementation between members in the 
quasispecies has been demonstrated in PV-infected mice [23]. In a wild-type viral population, some 
variants allow others to reach the brain after intramuscular injection, whereas a PV mutant with high Viruses 2011, 3                         
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fidelity polymerase has a reduced viral diversity that prevents such complementation, called 
cooperation [23]. A reduced cooperation capacity confers an attenuated phenotype to the mutant virus. 
In the presence of a defined selective pressure, the high fidelity mutant has a decreased fitness as 
compared to a PV with wild-type polymerase [24]. Together, these findings suggest that RNA viruses 
such as PV have evolved suboptimal viral polymerase fidelity to permit rapid adaptation to new 
environment, in particular in various host tissues [24,25].  Vignuzzi  and colleagues  (2008)  [25] 
proposed to engineer attenuated virus vaccines with increased replication fidelity to improve their 
genetic stability and their safety.  
Figure 2. Reported poliomyelitis outbreaks due to circulating vaccine-derived polioviruses 
(cVDPVs) (since 1988). The country, the type of implicated cVDPVs, the year of the 
outbreak and the number of reported cases are indicated. Data are those available from 
WHO/HQ on 3 May 2011 [11]. 
 
 
Different molecular clocks for PV based upon the rates of substitutions into the capsid-encoding 
region have been calibrated. In particular, the rapid evolution of the clocks of total substitutions, 
synonymous substitutions and synonymous transitions can be used to estimate the dates of divergence 
of closely related viruses [17]. However, the lengths of successive PV infections in various hosts and 
that of PV chronic infection in a single immunodeficient host cannot be distinguished using these 
molecular clocks. Microarray analysis has been proposed to monitor the evolution of such highly 
divergent VDPVs [26].  
Some specific amino acid alterations in VDPVs can lead to the modification of individual epitopes. 
However, this antigenic variability does not appear to be primarily caused by, or lead to, a significant 
immune evasion [27]. Viruses 2011, 3                         
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Recombination between viral RNA genomes is a well-known phenomenon for enteroviruses   
[28–31]. There are two main non-exclusive models of RNA recombination: A copy-choice, or 
replicative mechanism with RNA template switching during negative strand synthesis [32], and a 
non-replicative joining of RNA fragments [33].  It is likely that the majority of homologous 
recombination events occur by template switching during viral RNA replication.  
V. Agol's laboratory analyzed the primary structure of crossover regions of intertypic PV 
recombinants [34]. They showed that recombination sites were located in genomic regions having a 
potential to form secondary structures. Nonrandom distribution of the crossover sites appeared to be 
due to two factors: the existence of preferential sites for recombination and selection against 
recombinants with a lowered level of viability [35]. Using PV mutants with altered spacing of 
regulatory elements in the IRES, pseudorevertants suggested that RNA rearrangements (some 
recombinations, deletions, insertions) occur following pausing of the nascent strand, dissociation of the 
complex of the 3Dpol and 3' end of the nascent strand, annealing of the nascent strand with the second 
template, and resumption of viral RNA synthesis [36]. The analysis of a large number of intertypic PV 
recombinants has also shown that cross-overs are correlated with distinctive properties of the parental 
RNA sequences including domains of elevated homology and of high U-A content at close proximity 
to recombination sites [37]. In addition, the analysis of studies of genetic recombination in a replicative 
cell-free system in vitro and in infected tissue culture cells in vivo have led to the observation that 
temperature strongly influences the loci at which cross-over between the two PV RNA strands 
occurs [38].  
Under certain circumstances, non-replicative joining of viral RNA fragments may occur [33]. This 
phenomenon was demonstrated with pairs of viral RNA fragments corresponding to the 5' NC region 
of the genome on the one hand, and a viral genome harboring lethal mutations, such as deletions, in the 
same 5'NC region. Some fragments with interruptions within the sequence of the 3Dpol were also used 
so that joining of the fragments was a prerequisite for the appearance of this enzyme [39]. Many 
recombinant PV were isolated following co-transfection of these pairs of non-infectious RNA 
fragments into monkey cells. Therefore, two RNA fragments could be efficiently ligated provided the 
5'-  and 3'-partners were in 3'-phosphate and 5'-OH forms, respectively [39]. Some recombinants 
appeared to be generated by multiple recombination events. Some imprecise “monstrous” but viable 
recombinants harboring additional sequences were genetically unstable. The additional sequences 
corresponded to portions of a 3' terminal 3Dpol, 3'NC and poly A sequence. Both imprecise and 
precise (homologous) viable PV recombinants were obtained. There were recombination hot spots that 
did not preferentially map to regions of identity in the partners, but the corresponding RNA segments 
could be folded into secondary structures similar to known ribozyme motifs  [33]. This type of 
recombination might have resulted from transesterification reactions. Although probably rare in nature, 
such events may result in the creation of novel viral genomes, and may play a pivotal role in evolution 
of RNA viruses.  
Overall, recombination among enteroviruses is frequent [40] and Lukashev and colleagues [28] 
proposed that enterovirus species consist of a finite set of capsid genes responsible for different 
serotypes and a continuum of nonstructural protein genes that seem to evolve in a relatively 
independent manner. Recombination mostly occurs between members of the same species, and most Viruses 2011, 3                         
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often outside of the capsid encoding region [31,41]. Nevertheless, recombination in the PV capsid 
proteins VP1 and VP2 has been sometimes found [42–48]. 
3. Vaccine Associated Paralytic Poliomyelitis and Inter-Typic Recombinants 
As mentioned above, the  rate of PV evolution is extremely high and mainly due to the high 
frequency of nt misincorporation in RNA synthesis, [15]. This could be the cause of very rare cases 
(1 case per 0.2–2.5 million OPV doses) of vaccine-associated paralytic poliomyelitis (VAPP), which is 
clinically indistinguishable from poliomyelitis caused by wild-type PV. The first cases of VAPP 
appeared the year of licensure of the monovalent OPV vaccine and were associated with the Sabin 3 
strain [49]. Mutated neurovirulent vaccine-derived strains were found in the gut of healthy vaccinees 
and in the gut and CNS of VAPP patients and most strains were intertypic vaccine/vaccine 
recombinants [50,51]. The underlying cause of VAPP is the genetic instability of OPV strains, as key 
substitutions conferring the attenuated phenotype of Sabin strains have been frequently found to be 
reverted in isolates from VAPP cases [52]. VAPP is most frequently associated with Sabin 3,   
followed by Sabin 2 [3]. The higher degree of attenuation of Sabin 1 is likely to prevent VAPP 
association with this strain.  
Moreover, the trivalent  nature of OPV provides ideal conditions for intertypic recombination 
between the attenuated strains of the three PV serotypes. Recombination, which is a very frequent 
event in PV evolution, allows the virus to eliminate adverse mutations and is likely to provide 
adaptation of the virus to the environment. In order to understand the evolution of vaccine strains 
during their replication in humans and to confirm the etiology of VAPP, numerous studies focussed on 
the characterization of vaccine-derived strain genomes by double  restriction fragment length 
polymorphism assay (RFLP) [43,51,53,54]. Recombination is most often detected in Sabin 2 and 
Sabin 3 derived isolates and rarely in Sabin 1 [50–52,55,56]. However, sequences of Sabin type 1 
origin are regularly found in S2/S1 and S3/S1 recombinant strains [57]. The reasons for this profound 
imbalance are still unknown but the preservation of viable secondary structures has been proposed as a 
possible reason for this selection [58]. The localization of certain types of recombination junctions in 
specific genomic regions depends on the association of strains, and certain regions of the PV genome 
seem to be hotspots for recombination. Most of the recombinants with a Sabin 3 capsid present 
recombination sites in the 2C genomic region, while recombination sites of those with a Sabin 2 capsid 
were preferentially located in the 3Dpol region [53,58,59].  Moreover, recent studies revealed a 
preferential hotspot for recombination between Sabin 3 and Sabin 2 strains, located at the 3′ end of 
VP1 [43,44,47,60]. Although the vast majority of recombinants present a single site of recombination, 
multiple sites of recombination have been identified in some isolates [43,53,54,56–59,61–63], 
underlining the high frequency of recombination in the PV genome, and its genetic flexibility.  
In a few cases, vaccine/nonvaccines poliovirus recombinants have been found from patients with 
VAPP [51,61]. In these recombinants vaccine-specific segments of the Sabin virus genome have been 
replaced by sequences derived from wild PVs or, perhaps, from non-polio enteroviruses (NPEVs). In 
countries where wild-type PV still circulates, vaccine PV and vaccine/wild recombinants have been 
frequently isolated from the VAPP patients [54]. Recombination between wild and vaccine strains has Viruses 2011, 3                         
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also been identified in type 1 wild/vaccine recombinant PV sharing a 367 nt block of Sabin 1-derived 
sequence spanning the VP1 and 2A genes that circulated in China from 1991 to 1993 [42,62]. 
4. Vaccine-Derived Poliovirus 
VDPVs are usually characterized as OPV-derived PV of the three serotypes with more than 1% nt 
sequence divergence from the Sabin strains in the VP1 region. OPV strains with less than 1% 
divergence are generally considered as OPV-like [3]. The extent of divergence is roughly proportional 
to the duration of viral replication or circulation since administration of the initiating OPV dose. 
Nucleotide substitutions in PV are known to accumulate at an overall rate of about 1% per year and the 
evolution rates appear to be similar for the three serotypes of PV [64–68]. This implies that VDPVs 
had been circulating or multiplying for more than one year, which is far beyond the normal average 
period of multiplication of OPV in vaccinees, rarely exceeding eight weeks [69]. It is obvious that this 
cutoff value of 1% sequence divergence has to be considered cautiously since OPV-derived strains 
with more than 0.5% sequence divergence may be considered as the product of abnormal 
multiplication and circulation and can be implicated in disease. In fact, rare OPV-derived type 2 OPV 
strains with more than 0.5% have been implicated in poliomyelitis and some of them were shown to be 
the source of more diverged VDPV lineages [70]. The term pre-VDPVs including type 2 OPV-like 
strains with 0.5–1% nt sequence divergence was recently employed [70]. Although this term presently 
makes sense for type 2 strains it is likely that it will possibly be applied to other serotypes if more 
polio cases due to type 1 and 3 OPV strains with similar percentage of nt divergence are reported. 
In fact, the highest sequence divergences were reported for immunodeficiency-associated VDPV 
(iVDPV) isolated from immunodeficient patients who have become chronical excretors of the virus 
following OPV exposure and for ambiguous VDPVs (aVDPVs) that are OPV-derived strains either 
isolated from patients with no known immunodeficiency or not associated  with an outbreak, or 
environmental isolates [3].  
Chronic PV infection can occur following administration of OPV to individuals with primary 
immunodeficiencies, in particular hypogammaglobulinemia [65]. Long-term excretion of iVDPVs can 
last from six months to more than twenty years and is a difficult condition to treat [43,71]. Type 1 and 
type 2 iVDPVs were found in patients following an estimated duration of excretion of 7.6 and   
19 years, respectively (10% and 18% nt sequence divergence, respectively) [71,72]. They accumulate 
numerous mutations and evolve toward a non-temperature sensitive and neurovirulent phenotype 
[73,74]. Different PV strain lineages in the same immunodeficient host, and recombination between 
these strains have sometimes been detected [74], as well as intertypic vaccine/vaccine recombinants [43].  
Chronic PV excretors are not always identified, but highly divergent neurovirulent aVDPVs with 
characteristics of iVDPVs were detected in sewage when regular surveillance of the environment was 
performed [75–77]. Type 2 and type 3 aVDPVs with up to 13.7% sequence divergence were isolated 
from sewage in Slovakia and  Estonia suggesting that they had been replicating in one or more 
individuals for approximately 10–13 years [68,78]. In addition, a type 2 aVDPV lineage has been 
recurrently isolated over a six year period from sewage in Israel [79,80]. Nucleotide sequence 
divergence values from 8.7% to 14.7% suggested that the first exposure to the vaccine strain occurred 
about 15 years before the last isolate uptake [80]. More recently, search for infectious PV in sewage Viruses 2011, 3                         
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samples in Finland led to the discovery of genetically highly divergent type 1 and 3 aVDPVs showing 
from 12.3% to 14.6% nt divergence from OPV strains  [77]. The extent of sequence divergence 
suggests that the viruses had been replicating in human for more than 10 years. These type 2 and type 
3 VDPVs had intertypic recombinant genomes [77]. It is likely that all these highly divergent aVDPVs 
had been shed from a few chronically infected individuals.  
Considering the high percentage of recombinants in vaccinees [68,77,79–81], it is not surprising 
that certain iVDPVs and many aVDPVs have been shown to be intertypic recombinants between 
different types of OPV strains. To our knowledge, recombination between OPV and non-vaccine 
strains (either PV or other HEV-C) has never been reported in i-VDPVs or aVDPVs, even in those 
showing important genetic drifts. Most if not all of these VDPVs displayed the characteristics of wild 
PV strains. In contrast to genuine  OPV strains, they can replicate at high temperature and are 
pathogenic in animal models [68,79–81]. They are modified in certain antigenic sites as shown by their 
poor reactivity with certain neutralizing monoclonal antibodies and the highly divergent ones can show 
lower reactivity with sera from vaccinees compared to the genuine OPV strains [68,80,81]. These 
VDPVs constitute a reservoir of potentially pathogenic strains that make any attempt to eradicate PVs 
more complex. Finding unknown PV excretors remains quite difficult and no efficient treatment has 
been found to cure chronically infected individuals [71,81,82]. The development of antiviral molecules 
capable of clearing enteroviruses from the gut of long-term excretors remains highly required. 
5. Circulating Vaccine-Derived Polioviruses Implicated in Polio Outbreaks 
cVDPVs are associated with sustained person-to-person transmission and have been implicated in 
many poliomyelitis outbreaks reported since 2000 (Figure 2). The first cVDPV outbreak to be detected 
occurred in 2000–2001 in Hispaniola (which is divided into the Dominican Republic and Haiti) [83]. A 
total of 21 confirmed cases of AFP were detected, divided into 13 cases in Dominican Republic and 
eight  cases in Haiti, including two fatal cases. All patients were incompletely vaccinated or 
unvaccinated, and cases occurred in communities with very low rates of trivalent OPV vaccine 
coverage (from 7% to 40%). The virus isolates were unrelated to any known wild PV (<82% VP1 nt 
sequence identity), but closely related to the Sabin 1 OPV strain (98% VP1 nt sequence identity). 
According to the evolution rate within VP1 of the cVDPVs, it has been estimated that the initiating 
OPV dose occurred in late 1998 or early 1999. The cVDPV had recovered two of the most important 
biological properties of wild PV: the capacity to cause severe paralytic disease in humans and the 
capacity for extensive human-to-human transmission. These viruses were all recombinants presenting 
a 5′NC and capsid region sequences derived from Sabin 1, whereas most of the non-capsid sequences 
were derived from other HEV-Cs (Figure 3). 
This first reported outbreak underlined that low OPV coverage carried a risk of cVDPV emergence 
and obliged WHO to reconsider its strategies both for polio immunization and PV surveillance. 
Supplemental testing requirements to increase sensitivity for detecting cVDPV were implemented, 
allowing another outbreak to be detected in early 2001 in the Philippines. Viruses 2011, 3                         
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Figure 3. Genetic features of recombinant genomes from cVDPVs implicated in different 
outbreaks. A schematic view of the genetic organization of the poliovirus genome is given 
(see also Figure 1). The presence of vaccine-derived sequences are indicated above the 
cVDPV genomes (mutated Sabin 1 or 2 sequences) as well as the non-vaccine sequences 
derived from other HEV-Cs (HEV-C sequences). Patterns differentiate HEV-C sequences 
that differed significantly from each other. Data are modified from [83] (Hispaniola), [84] 
(Philippines), [67] (Egypt) and [85] (Nigeria). 
 
 
Three cases of acute flaccid paralysis associated with cVDPVs were reported in the Philippines 
during the period March 15–July 26, 2001. In contrast to the first outbreak, this outbreak appeared in 
an area where the vaccination rate was high (nearly 80%). The gap between different vaccination 
campaigns appeared as a clue for emergence of virulent cVDPV strains. The Philippines cVDPV 
isolates, like other cVDPVs so far, present recombinant non-capsid sequences derived from non-polio 
HEV-Cs [84,86]. The complete genomic sequencing indicated recombination between Sabin 1 and 
other HEV-Cs. Finally, the sequence relationships among the cVDPVs and Sabin 1 suggested that 
cVDPVs originated from an OPV dose given in 1998 or 1999. 
Another outbreak, due to type 2 cVDPVs, was reported retrospectively in Egypt following the 
analysis of type 2 PV strains that were thought to be one of the last circulating wild type 2 strains [67]. 
From 1988 to 1993, 30 cases of poliomyelitis associated with PV type 2 were found in seven 
governorates. Recent molecular analysis of the major capsid protein VP1 revealed that the isolates 
were related to the Sabin 2 OPV strain and unrelated to the wild type 2 PV previously indigenous to Viruses 2011, 3                         
 
 
1470 
Egypt. The sequence properties of the isolates suggested that cVDPVs emerged in Egypt with an OPV 
dose given in 1983 and that low OPV coverage allowed spread of infection during at least a period of a 
decade. Sequences analysis of both an early and a late cVDPV revealed that the 5'NC, non-structural 
and 3'NC  genomic regions were derived from HEV-C, confirming the fact that OPV strains and   
HEV-Cs have frequent genetic exchanges [67].  
In Madagascar, an outbreak occurred in the southern province of Toliara, between October 2001 
and April 2002, where the last wild-type PV had been reported in October 1997 [87]. Five cases of 
AFP associated with type 2 cVDPVs occurred in two areas in 2001 and 2002. None of the patients had 
been fully immunized against poliomyelitis. The type 2 cVDPVs isolated from patients represented 
two groups depending on the area and two subgroups depending on the time of the outbreak. The 
urban isolates differed from the Sabin 2 strain at ∼1% of VP1 nt, whereas the rural isolates differed 
from Sabin 2 at ∼2.5% of VP1 nt. Sequencing of the cVDPV genomes confirmed the presence of two 
independent recombinant cVDPV lineages with most of the 3' half of the genomes derived from 
HEV-C species [88].  
Despite nationwide vaccination campaigns to interrupt circulation of cVDPVs in Madagascar, 
another outbreak (5 polio cases) occurred in the same province from April to August 2005. This 
outbreak presented particularly interesting features including that it was not only associated with type 
2 cVDPVs, but also with type 3 cVDPVs. Search for viruses in the stool samples of healthy children 
living in close proximity to the patients showed that cVDPVs were present in 7% of children 
indicating that these PV were well-established in the population. VP1 and P1 nt sequences, were from 
1.0% to 2.7% divergent from those of the genuine OPV strains, indicating that these strains have been 
circulating during about 12 to 32 months according to different transmission chains [89,90]. The 
cVDPV of both types presented PV/HEV-C recombinant genomes, confirming that cVDPVs are 
associated with the co-circulation of HEV-Cs and with genetic exchanges between both partners. 
Despite the fact that these cVDPVs were isolated in different and distant districts of the same province 
of Madagascar they shared common genetic features (Figure 4). The type 2 cVDPV genomes shared 
similar 5' halves constituted of the non-vaccine HEV-C sequences in the 5'NC region and identical 
recombination sites with the neighboring OPV sequences. In addition, some type 2 and the type 3 
cVDPV isolates shared the same 3' end that was made of non-vaccine HEV-C and Sabin 3 sequences 
with identical recombination sites. All these results indicated an intense circulation of enterovirus 
strains and a rapid evolution between PV and HEV-C, involving multiple rounds of intratypic and 
intertypic recombination in a short period of time and in a restricted geographic area [89,90]. 
Since the first reports of polio outbreaks, new epidemics due to the circulation of cVDPVs were 
reported (see Figure 2 and [11]). Most of these outbreaks implicated only a limited number of up to a 
few dozen cases. However, a severe outbreak due to type 2 cVDPVs was rife in Nigeria from 2005 for 
more than six years with more than 300 cases of poliomyelitis [70,91,92]. In general, the studied VP1 
nt sequences of cVDPV isolates have diverged from parental OPV strains by only 1–3.5%, which 
indicates circulation times of no longer than 1–4 years and reversion of the attenuated phenotype of 
Sabin strains was observed [83,84,87,93,94]. However, nucleotide divergence of up to 6% could be 
found recently in Nigeria [95]. It is striking that the cVDPVs implicated in most outbreaks mentioned 
above were due to recombinant strains which were the product of genetic exchanges between OPV 
strains and other HEV-Cs (Figures 3 and 4 and Table 1) [3,70,89,96] including the recombinant type 2 Viruses 2011, 3                         
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cVDPVs implicated in recent polio outbreaks in India and in Democratic Republic of Congo [95,97]. 
Up to now only one polio outbreak with two cases of disease occurring in Guizhou Province, China, 
was due to a non-recombinant cVDPV Sabin 1 lineage with 1.0%–1.2% nt divergence [98].  
Figure 4. Genetic features of recombinant cVDPV genomes from Madagascar. Some 
cVDPVs isolated in Madagascar in 2002 and 2005 are represented as in Figure 3. 
Non-vaccine sequences (HEV-C sequences) showing similarity with those of coxsackie A 
viruses (CV-A11, -A13, -A17) isolated in the same province are indicated. Data are modified 
from [88–90]. 
 
 
Although all the cVDPV outbreaks occurred in low-income countries, clear indication of circulation 
of vaccine-derived viruses could also be found in industrialized countries with temperate climates and 
middle population density if the following conditions are present: Wide immunity gap, number and 
density of immune susceptible persons, high birth rate and deficiencies in hygiene/sanitation. Despite 
high global vaccine coverage with OPV, a type 1 VDPV has been isolated from one AFP case and 
seven healthy children (contacts) living in a small town in Romania in a minority with low vaccine-
coverage and bad hygiene conditions [55]. The isolated strain exhibited a tripartite intertypic 
recombinant genome Sabin 1/ Sabin 2/ Sabin 1 derived from a common ancestor strain, with 1.2% nt 
substitutions in the VP1 capsid protein coding region, indicating a circulation time of about 14 months. 
Moreover, an imported type 1 VDPV differing by 2.3% nt sequence from the genuine Sabin 1 strain 
was found in many children living in an undervaccinated community in Minnesota [99]. Suspicion of 
long-term circulation was also inferred from the analysis of divergent OPV strains isolated from 
patients with AFP in the Russian Federation [26,52,100]  or from non-immunized populations in 
Byelorussia  [101]. Therefore, even in developed countries, small populations with low vaccine 
coverage, living in globally well-vaccinated countries can be the origin of cVDPV emergence and 
circulation, reaffirming the importance of a well-organized AFP surveillance program. Viruses 2011, 3                         
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6. Genetic Features of Recombinant cVDPV Genomes 
All recombinant cVDPV genomes described so far had kept at least the entire region encoding the 
capsid proteins of OPV strains (with more than 1% nt substitutions), and some or all of the rest of the 
genome, particularly the region encoding non-structural proteins, originates from other HEV-Cs 
[67,83,84,88–90]. Most of them showed the 3'-half of their genome derived from non-OPV sequences 
with recombination sites located in proteins 2A or 2B [67,83,84,88]. Nevertheless, recombination sites 
could be found elsewhere in the P2 or the P3 region [89,90]. In addition, many type 2 VDPV lineages 
displayed a great part of their 5'NC region derived from non-OPV HEV-Cs. In this case some of them 
had only kept the region encoding the capsid proteins from the genuine OPV strains (Figures 3 and 4). 
More complex genomic structures were found in Madagascar during the 2005 outbreak. Type 2 
cVDPV lineages showed a mosaic quadripartite recombinant genome constituted of non-OPV sequences 
in the 5'NC and in the P2/P3 regions, flanking the type 2 OPV capsid sequences and, moreover, type 3 
OPV sequences ended the 3' termini of the genome (Figure 4) [89].  
When sequenced, all major attenuation determinants located in the 5'NC OPV genomic regions and 
known to affect the efficiency of genomic translation were found to have reverted to wild type nt. 
These determinants are located at nt positions 480, 481 and 472 of the Sabin 1, 2 and 3 OPV strains, 
respectively. In addition, in type 1 cVDPVs, codons implicated in attenuation were sometimes mutated 
in capsid proteins, in particular at residues 65 of VP4, 225 of VP3 and 106 of VP1 [83,84,102]. 
Residues 143 of VP1 and 91 of VP3 implicated in the attenuation of the type 2 and 3 OPV strains, 
respectively, were systematically mutated in the corresponding cVDPVs [67,88–90]. 
7. Recombination Partners of PV in cVDPVs 
The finding that some recombinant cVDPV genomes have kept only the capsid genomic regions 
from the genuine OPV strains [54,61,67,89,90] indicated that all the other parts of the genome can be 
shared by other HEV-Cs. The enterovirus capsid, rarely subject to recombination [31], appears as the 
main viral structure that determines virus types. The type of wild PV and other HEV-Cs refers thus to 
the structure and sequences of the capsid for a given virus. Actually, a good correlation was found 
between the nt sequences of the capsid protein VP1 and the serotype of known enteroviruses 
[103,104]. Comparing nt VP1 sequences of a HEV with those of prototype HEV strains has become 
the main method to identify the type of an isolate. 
HEV-Cs were the suspected partners of recombination with OPV strains, because of the higher 
similarity of their genomic sequences with that of PV, as compared to those of other HEVs belonging 
to the HEV-A, HEV-B or HEV-D species [105]. In fact, vaccine-derived recombinants with 
non-vaccine sequences were isolated in several countries (Romania, Egypt, Nigeria, Democratic 
republic of Congo, India) in which wild type strains were still circulating [54,61,67,85]. In these cases, 
recombination between OPV and wild-type PV strains could be questioned. However, OPV/HEV-C 
recombinants were also isolated in countries (Hispaniola, Philippines, Cambodia and Madagascar) in 
which wild PVs had been eradicated [83,84,88,89,94]. Therefore, the hypothesis of recombination 
between OPV and co-circulating non-PV HEV-Cs was put forward.  Viruses 2011, 3                         
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Table  1.  Recombinant features of circulating vaccine-derived  polioviruses (cVDPVs) 
implicated in polio outbreaks. The type of capsid is indicated as well as the presence of 
non-vaccine sequences (HEV-C) in at least part of the non-structural genomic regions. 
Niger and Chad cVDPVs are linked to the Nigeria outbreak.  
Country 
Number of 
Cases 
Year(s) of 
Outbreak 
cVDPV 
capsid/non capsid coding region  
References 
Indonesia  46  2005  OPV type 1 / HEV-C  [96] 
China  2  2004  OPV type 1  [98] 
Philippines  3  2001  OPV type 1 / HEV-C  [84] 
DOR/Haiti  21  2000–01  OPV type 1 / HEV-C  [83] 
Egypt  30  1988–1993  OPV type 2 / HEV-C  [67] 
Nigeria  338  2005–2011  OPV type 2 / HEV-C  [85] 
Chad  1  2010  OPV type 2 / HEV-C  [95] 
DR Congo  37  2008–10  OPV type 2 / HEV-C  [95] 
Niger  5  2006–2010  OPV type 2 / HEV-C  [95] 
Cambodia  3  2005–06  OPV type 3 / HEV-C  [106] 
India  16  2009–10  OPV type 2 / HEV-C  [97] 
Madagascar  10 
2001–02  OPV type 2 / HEV-C 
OPV type 3 / HEV-C 
[88] 
[90]  2005 
 
This hypothesis was confirmed in Cambodia, in which a Sabin 3-/HEV-C recombinant (Cambodia 
02) was isolated from an AFP case in 2002 [94]. An attempt to identify the putative recombinant 
counterpart was done by partially sequencing non-PV HEV-Cs which had been isolated from patients 
with AFP between 1999 and 2003 in the country. The results indicated that parts of the P2 and the 
3Dpol genomic regions of the strain Cambodia 02 were closely related to homologous sequences of 
CAV strains of type 17 and 13 (CV-A17 and CV-A13), respectively. These results suggested that the 
P2 and the 3DPol genomic regions of the Cambodian VDPV were derived from a HEV-C strain 
genetically related to indigenous CV-A17 and CV-A13 strains circulating in Cambodia. Concerning 
the type 2 recombinant cVDPVs isolated  in Madagascar, the putative parents of their non-PV 
sequences were searched for in HEV isolates present in stool samples from healthy children [88]. 
These samples were collected in the district where the AFP cases were reported in 2002, in villages 
located in a small area, a few kilometers away from each other. 21% of the samples were positive for 
HEVs and 80% of these HEVs belonged to the HEV-C species including six different types (CV-A11, 
CV-A13, CV-A17, CV-A20, CV-A24 and HEV99) [88,90]. Partial sequencing suggested that parts of 
the P2 and 3Dpol genomic regions of the cVDPVs isolated in 2002 were derived from HEV-C strains 
genetically related to Madagascar CV-A17 and CV-A13 strains, respectively. Non-PV sequences 
present in the cVDPV lineages isolated in 2005 were also related to sequences present in local 
CV-A13, CV-A17 and possibly CV-A11 (Figure 4) [90].  
These results indicated that most of the genomes of the cVDPVs were complex mosaic genomes 
with sequences derived through genetic recombination from different OPV and CAV strains. CV-A13 
and CV-A17 appeared from these studies as the preferred partners for recombination with OPV strains. Viruses 2011, 3                         
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8. PV, a Member of a Dense and Diversified HEV-C Ecosystem 
In fact, the search for the non-PV partners that recombined with OPV strains to give cVDPVs in 
Cambodia and in Madagascar led to the discovery of many co-circulating non-PV HEV-Cs 
[88,94,107]. In both countries the percentages of HEVs belonging to species C were high (38% and 
80%, respectively). Six to seven different HEV-C types were found each year in Cambodia from 1999 
to 2003. A similar variety of HEV-C types co-circulating with recombinant cVDPVs was also found in 
Madagascar from samples collected over a few days, in a small area. A large variety of recombinant 
genotypes was found, increasing the diversity of this dense HEV-C ecosystem [88,108]. It is likely that 
PV has been always an active member of this ecosystem. OPV strains do have the natural propensity to 
interact with the other members of the HEV-C species when they come into contact. The presence of 
multiple HEV-C types is probably due to particularly favorable conditions (climate, poor sanitation, 
human genetics, etc.). Another non-exclusive hypothesis is that genetic and functional interactions 
among these different types contribute to maintain this viral diversity. 
Among the different co-circulating HEV-C types that have been identified so far in Cambodia and 
in Madagascar, only PV is known to be a major human pathogen. CV-A1, CV-A11, -13, -17, -20 are 
not known to be implicated in particular severe disease outbreaks and may be considered as poorly- or 
non-pathogenic viruses [109]. Only CV-A21 and CV-A24 have been reported to be implicated in 
common cold outbreaks. CV-A24 is known to be the causative agent of important hemorrhagic 
conjunctivitis outbreaks [109]. PV appears thus as the “black sheep” of a much more quiet “viral 
tribe”. It differs also from the other HEV-C members by many biological properties including binding 
on a specific cellular receptor CD155 whereas most of the others are thought to bind to ICAM-1. This 
HEV-C ecosystem gathers thus very different viruses even though they belong to the same species. 
9. Impact of Non-PV Sequences on the Characteristics of cVDPVs—in vitro-Made Recombinants 
Most of the cVDPVs that have been described so far share phenotypic characteristics including the 
capacity to induce poliomyelitis in humans and in transgenic mice expressing CD155, the human 
cellular receptor for PV [67,83,84,88]. In addition, in contrast to the genuine OPV strains, cVDPVs 
can efficiently multiply at supraoptimal temperature. These characteristics correlate with the 
modification of genetic determinants implicated in attenuation and temperature sensitivity. This could 
be done through mutation or through recombination with non-OPV sequences. Actually, no phenotypic 
character that can be evaluated in laboratories can distinguish cVDPVs from wild counterparts.  
It has recently been reported that, in Nigeria no significant differences could be found in the clinical 
severity and attack rate of paralysis among the cases due to cVDPVs and those due to wild PVs. Most 
of the cVDPVs that have been studied in details and in some cases with batteries of neutralizing 
monoclonal antibodies, showed modifications in some neutralizing antigenic sites [66,83,84,88]. 
However, these antigenic modifications, resulting from mutations in the capsid genomic region, have 
no dramatic influence on the efficiency of the OPV since OPV vaccine responses organized following 
cVDPV outbreaks were capable of getting rid of the implicated viruses [110]. 
Genetic recombination is a common evolution mechanism that is thought to contribute at least to the 
repair of deleterious mutations in genomes [13]. However the role of genetic exchanges in the Viruses 2011, 3                         
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characteristics of OPV/HEV-C recombinant is still unclear. The characteristics of the PV genome 
(small size, non-segmented, positive polarity, infectious RNA) facilitated genetic engineering and the 
construction of chimeric PV. This allowed to locate viral determinants such as those involved in 
neurovirulence/attenuation, temperature sensitivity, host cell tropism, and to investigate the 
mechanisms of recombination. It also allowed the impact of recombination between PV and other 
HEVs to be investigated.  
The genetic exchanges between a wild type 1 PV (PV1) and CAV, in particular CV-A20, have been 
studied with engineered chimeras [111]. The genetic structure resembling that of cVDPV, with a PV 
capsid, consistently survived much better than did their reciprocal counterparts with a CAV capsid. 
Similar results were obtained with other serotypes, indicating that genetic recombination between PV 
and CAV showed a parent-specific asymmetry in compatibility [111]. In addition, the inter-virus 
genetic distance of parents modulated compatibility. The recombination frequency between PV1 and 
CV-A20 was calculated to be 10
−6, similar to frequencies observed between heterotypic PV strains. 
The cross-overs mapped to the P2 region encoding nonstructural proteins. Interestingly, the 
PV1/CV-A20 recombinants were nearly as neurovirulent in Tg-PVR mice as wild PV1 [111]. This 
suggested that some CAVs can be recombination partners of PV in nature. More recently it was shown 
that a direct interaction between the non-structural protein 2C and the capsid protein VP3 is required 
for enterovirus morphogenesis [112]. A non-functional interaction between the protein VP3 of some 
CAVs and the protein 2C of PV could explain the defect in multiplication of CAV/PV recombinants 
[111,112] and their apparent absence in nature [88].  
To investigate the impact of genetic exchanges between PV and HEV-C species on the 
characteristics of recombinant viruses, Riquet and colleagues generated chimeric viruses with various 
cross-over regions between one type 2 cVDPV and the original vaccine Sabin 2 strain [113]. Protease 
2A from cVDPV played only a minor role or no role at all in the pathogenicity of these in vitro made 
recombinants. Results indicated that the other HEV-C sequences present in this cVDPV contribute to 
its characteristics, including pathogenicity, suggesting that PV/CAV recombination may favor the 
emergence of cVDPVs [113].  
More recently, Jegouic  and colleagues  investigated whether CV-A17 can act as a  recombinant 
partner of PV  [114]. They generated recombinant constructs combining the genetic material of a 
CV-A17 isolate from Madagascar with that of the type 2 vaccine strain and that of a type 2 cVDPV. 
PV/CV-A17 recombinants were all viable. The recombinant in which the 3' half of the vaccine strain 
genome had been replaced by that of the CV-A17 genome yielded larger plaques and was less 
temperature sensitive than its  parental strains. It was almost as neurovirulent as the cVDPV in 
transgenic mice expressing the PV cellular receptor gene. This study showed that a CV-A17 isolate 
co-circulating with a PV/HEV-C recombinant cVDPV can be a recombination partner for PV. These 
results also suggested that recombination can, at least in some cases, have a direct effect on the key 
phenotypic characteristics of recombinants, such as replication level, and may thus favor the 
emergence of pathogenic cVDPVs. Viruses 2011, 3                         
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10. A Model of Genetic Plasticity and Emergence 
Complex vaccine-derived multi-recombinant PVs including a penta-recombinant PV implicating the 
three serotypes have been reported [48,58]. Multi-recombinants of OPV strains with wild PVs were 
also described [42,54,61,62]. In addition, genetic exchanges between wild PVs were reported [62,115]. 
Actually, different complex mosaic genomes implicating different serotypes of OPV strains and 
different genomic fragments related to different CAV types were found in Madagascar in a short 
period of time  [89,90]. Together these data show that a given PV type can evolve rapidly and 
intensively through recombination by multiplying and circulating in close interaction with other PV or 
HEV-C types. With regard to the biodiversity of HEV-Cs found in a single district of Madagascar, and 
to the rapid spread, evolution and diversification of the recombinant cVDPV genotypes in a short 
period of time, it is tempting to propose that, in this kind of ecosystem, intratypic as well as intertypic 
recombination between HEVCs is a permanent and usual mechanism of genetic plasticity that in 
addition to mutations generates genetic and phenotypic viral diversity.  
Studies with engineered PV/CAV recombinants have shown that recombination can affect—
or not—the multiplication of recombinant viruses [111–114]. Similarly, experiments consisting in 
evaluating the pathogenicity of different in vitro-made PV/CAV recombinants in mice suggested that 
recombination can be neutral or can modulate the pathogenicity of recombinants [111,113,114]. These 
results suggest that the genetic plasticity associated with recombination events could either favor or 
affect the fitness of these viruses and their capacity to circulate in the human population and, 
incidentally, could make them more or less pathogenic. 
Since most cVDPVs implicated in polio outbreaks are OPV/HEV-Cs recombinants, it is likely that 
the genetic interaction between OPV strains and other HEV-Cs provides the virus with another way to 
increase its capacities to multiply, to circulate and eventually to emerge as a pathogenic and epidemic 
strain. That the main genetic determinant affecting translation and neurovirulence of OPV strains in the 
5'NC genomic region is reverted either by mutation or by recombination in cVDPVs lend support to 
this idea [67,89,90]. We cannot completely exclude that viral interactions via intertypic recombination 
is a neutral consequence of the simultaneous presence of multiple HEV-C types. However, this 
hypothesis seems nowadays unlikely. 
11. Concluding Remarks 
The global public health program consisting of vaccination of the human population with OPV has 
been quite successful. However, the emergence of cVDPVs is one of the major issues threatening the 
benefit of the eradication program. In fact, the spreading of a huge amount of man-made attenuated 
vaccine virus in the human population allowed us to discover an unknown interaction between PV and 
the members of its natural ecological niche. This discovery is of tremendous importance in terms of 
medical as well as basic virology and underlines the interest to keep close contact between basic and 
medical sciences, in particular when viral human pathogens are concerned.  
Many questions still remain concerning the parameters and interactions contributing to the 
maintenance and evolution of the different HEV-C types in the same ecosystem and niche. The 
mechanisms allowing frequent co-infection of cells by different virus types, those contributing to the Viruses 2011, 3                         
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recombination process, and the factors implicated in the likely subsequent selection of certain 
recombinants are still poorly known.  
A better understanding of the environmental and viral factors shaping HEV-C genetic diversity and 
contributing to the emergence of cVDPVs will certainly allow to improve viral surveillance and 
vaccination strategies and to prevent outbreaks due to vaccine-derived recombinant polioviruses. 
Acknowledgments 
We are grateful to Laurent Blondel for helping us in preparing figures and to Bruno Blondel for 
critical reading of the manuscript. The program was financially supported by the Transversal Research 
Program PTR-276, the Agence Nationale pour la Recherche and the Agence Inter-établissements de 
Recherche pour le Développement (ANR 09 MIEN 019), the Fondation pour la Recherche Médicale 
(FRM DMI20091117313). We are also indebted to the Fondation Mérieux and the Rotary International 
for support. B. Holmblat was the recipient of a scholarship from Région Ile-de-France. 
Conflict of Interest 
Francis Delpeyroux served as an external expert to sanofi pasteur. 
References and Notes 
1.  Hirst, G.K. Genetic recombination with newcastle disease virus, polioviruses, and influenza. 
Cold Spring Harb. Symp. Quant. Biol. 1962, 27, 303–309. 
2.  Ledinko, N. Genetic recombination with poliovirus type 1. Studies of crosses between a normal 
horse serum-resistant mutant and several guanidine-resistant mutants of the same strain. Virology 
1963, 20, 107–119. 
3.  Kew, O.M.; Sutter, R.W.; de Gourville, E.M.; Dowdle, W.R.; Pallansch, M.A. Vaccine-derived 
polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol. 2005, 
59, 587–635. 
4.  Ohka, S.; Sakai, M.; Bohnert, S.; Igarashi, H.; Deinhardt, K.; Schiavo, G.; Nomoto, A. Receptor-
dependent and -independent axonal retrograde transport of poliovirus in motor neurons. J. Virol. 
2009, 83, 4995–5004. 
5.  Gromeier, M.; Wimmer, E. Mechanism of injury-provoked poliomyelitis. J. Virol. 1998,  72, 
5056–5060. 
6.  Ida-Hosonuma, M.; Iwasaki, T.; Yoshikawa, T.; Nagata, N.; Sato, Y.; Sata, T.; Yoneyama, M.; 
Fujita, T.; Taya, C.; Yonekawa, H.; et al. The alpha/beta interferon response controls tissue 
tropism and pathogenicity of poliovirus. J. Virol. 2005, 79, 4460–4469. 
7.  Lancaster, K.Z.; Pfeiffer, J.K. Limited trafficking of a neurotropic virus through inefficient 
retrograde axonal transport and the type i interferon response. PLoS. Pathog. 2010, 6, e1000791. 
8.  Koike, S.; Taya, C.; Kurata, T.; Abe, S.; Ise, I.; Yonekawa, H.; Nomoto, A. Transgenic mice 
susceptible to poliovirus. Proc. Natl. Acad. Sci. U. S. A. 1991, 88, 951–955. 
9.  Ren, R.B.; Costantini, F.; Gorgacz, E.J.; Lee, J.J.; Racaniello, V.R. Transgenic mice expressing a 
human poliovirus receptor: A new model for poliomyelitis. Cell 1990, 63, 353–362. Viruses 2011, 3                         
 
 
1478 
10.  Ohka, S.; Igarashi, H.; Nagata, N.; Sakai, M.; Koike, S.; Nochi, T.; Kiyono, H.; Nomoto, A. 
Establishment of a poliovirus oral infection system in human poliovirus receptor-expressing 
transgenic mice that are deficient in alpha/beta interferon receptor. J. Virol. 2007, 81, 7902–7912. 
11.  Polio global eradication initiative. Available online: http://www.polioeradication.org (accessed on 
15 May 2011). 
12.  Roberts, L. Infectious disease. Polio outbreak breaks the rules. Science 2010, 330, 1730–1731. 
13.  Agol, V.I. Molecular mechanisms of poliovirus variation and evolution. Curr. Top. Microbiol. 
Immunol. 2006, 299, 211–259. 
14.  Agol, V. Picornaviruses as a model for studying the nature of rna recombination. In The 
Picornaviruses; Ehrenfeld, E., Domingo, E., Ross, R.P., Eds.; ASM: Washington D.C., USA, 
2010; pp. 239–252. 
15.  Ward, C.D.; Stokes, M.A.; Flanegan, J.B. Direct measurement of the poliovirus RNA polymerase 
error frequency in vitro. J. Virol. 1988, 62, 558–562. 
16.  Ward, C.D.; Flanegan, J.B. Determination of the poliovirus rna polymerase error frequency at 
eight sites in the viral genome. J. Virol. 1992, 66, 3784–3793. 
17.  Jorba, J.; Campagnoli, R.; De, L.; Kew, O. Calibration of multiple poliovirus molecular clocks 
covering an extended evolutionary range. J. Virol. 2008, 82, 4429–4440. 
18.  Savolainen-Kopra, C.; Blomqvist, S. Mechanisms of genetic variation in polioviruses. Rev. Med. 
Virol. 2010, 20, 358–371. 
19.  Eigen, M. Viral quasispecies. Sci. Am. 1993, 269, 42–49. 
20.  Domingo, E.; Escarmis, C.; Sevilla, N.; Moya, A.; Elena, S.F.; Quer, J.; Novella, I.S.; Holland, 
J.J. Basic concepts in rna virus evolution. FASEB. J. 1996, 10, 859–864. 
21.  Lauring, A.S.; Andino, R. Quasispecies theory and the behavior of RNA viruses. PLoS. Pathog. 
2010, 6, e1001005. 
22.  Biebricher, C.K.; Eigen, M. The error threshold. Virus. Res. 2005, 107, 117–127. 
23.  Vignuzzi, M.; Stone, J.K.; Arnold, J.J.; Cameron, C.E.; Andino, R. Quasispecies diversity 
determines pathogenesis through cooperative interactions in a viral population. Nature 2006, 439, 
344–348. 
24.  Pfeiffer, J.K.; Kirkegaard, K. Increased fidelity reduces poliovirus fitness and virulence under 
selective pressure in mice. PLoS. Pathog. 2005, 1, e11. 
25.  Vignuzzi, M.; Wendt, E.; Andino, R. Engineering attenuated virus vaccines by controlling 
replication fidelity. Nat. Med. 2008, 14, 154–161. 
26.  Cherkasova, E.; Laassri, M.; Chizhikov, V.; Korotkova, E.; Dragunsky, E.; Agol, V.I.; Chumakov, 
K. Microarray analysis of evolution of rna viruses: Evidence of circulation of virulent highly 
divergent vaccine-derived polioviruses. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 9398–9403. 
27.  Yakovenko, M.L.; Cherkasova, E.A.; Rezapkin, G.V.; Ivanova, O.E.; Ivanov, A.P.; Eremeeva, 
T.P.; Baykova, O.Y.; Chumakov, K.M.; Agol, V.I. Antigenic evolution of vaccine-derived 
polioviruses: Changes in individual epitopes and relative stability of the overall immunological 
properties. J. Virol. 2006, 80, 2641–2653. 
28.  Lukashev, A.N.; Lashkevich, V.A.; Ivanova, O.E.; Koroleva, G.A.; Hinkkanen, A.E.; Ilonen, J. 
Recombination in circulating enteroviruses. J. Virol. 2003, 77, 10423–10431. Viruses 2011, 3                         
 
 
1479 
29.  Oprisan, G.; Combiescu, M.; Guillot, S.; Caro, V.; Combiescu, A.; Delpeyroux, F.; Crainic, R. 
Natural genetic recombination between co-circulating heterotypic enteroviruses. J. Gen. Virol. 
2002, 83, 2193–2200. 
30.  Santti, J.; Hyypia, T.; Kinnunen, L.; Salminen, M. Evidence of recombination among 
enteroviruses. J. Virol. 1999, 73, 8741–8749. 
31.  Simmonds,  P. Recombination and selection in the evolution of picornaviruses and other 
mammalian positive-stranded rna viruses. J. Virol. 2006, 80, 11124–11140. 
32.  Kirkegaard, K.; Baltimore, D. The mechanism of rna recombination in poliovirus. Cell 1986, 47, 
433–443. 
33.  Gmyl, A.P.; Belousov, E.V.; Maslova, S.V.; Khitrina, E.V.; Chetverin, A.B.; Agol, V.I. 
Nonreplicative rna recombination in poliovirus. J. Virol. 1999, 73, 8958–8965. 
34.  Romanova, L.I.; Blinov, V.M.; Tolskaya, E.A.; Viktorova, E.G.; Kolesnikova, M.S.; Guseva, 
E.A.; Agol, V.I. The primary structure of crossover regions of intertypic poliovirus recombinants: 
A model of recombination between rna genomes. Virology 1986, 155, 202–213. 
35.  Tolskaya, E.A.; Romanova, L.I.; Blinov, V.M.; Viktorova, E.G.; Sinyakov, A.N.; Kolesnikova, 
M.S.; Agol, V.I. Studies on the recombination between RNA genomes of poliovirus: The primary 
structure and nonrandom distribution of crossover regions in the genomes of intertypic poliovirus 
recombinants. Virology 1987, 161, 54–61. 
36.  Pilipenko, E.V.; Gmyl, A.P.; Agol, V.I. A model for rearrangements in RNA genomes. Nucleic. 
Acids Res. 1995, 23, 1870–1875. 
37.  King, A.M. Preferred sites of recombination in poliovirus RNA: An analysis of 40 intertypic 
cross-over sequences. Nucleic. Acids Res. 1988, 16, 11705–11723. 
38.  Duggal, R.; Wimmer, E. Genetic recombination of poliovirus in vitro and in vivo: Temperature-
dependent alteration of crossover sites. Virology 1999, 258, 30–41. 
39.  Gmyl, A.P.; Korshenko, S.A.; Belousov, E.V.; Khitrina,  E.V.; Agol, V.I. Nonreplicative 
homologous rna recombination: Promiscuous joining of RNA pieces? RNA 2003, 9, 1221–1231. 
40.  Simmonds, P.; Welch, J. Frequency and dynamics of recombination within different species of 
human enteroviruses. J. Virol. 2006, 80, 483–493. 
41.  Lukashev, A.N. Role of recombination in evolution of enteroviruses. Rev. Med. Virol. 2005, 15, 
157–167. 
42.  Liu, H.M.; Zheng, D.P.; Zhang, L.B.; Oberste, M.S.; Pallansch, M.A.; Kew, O.M. Molecular 
evolution of a type 1 wild-vaccine poliovirus recombinant during widespread circulation in china. 
J. Virol. 2000, 74, 11153–11161. 
43.  Blomqvist, S.; Bruu, A.L.; Stenvik, M.; Hovi, T. Characterization of a recombinant type 3/type 2 
poliovirus isolated from a healthy vaccinee and containing a chimeric capsid protein vp1. J. Gen. 
Virol. 2003, 84, 573–580. 
44.  Blomqvist, S.; Savolainen-Kopra, C.; Paananen, A.; El Bassioni, L.; El Maamoon Nasr, E.M.; 
Firstova, L.; Zamiatina, N.; Kutateladze, T.; Roivainen, M. Recurrent isolation of poliovirus 3 
strains with chimeric capsid protein vp1 suggests a recombination hot-spot site in vp1. Virus. Res. 
2010, 151, 246–251. Viruses 2011, 3                         
 
 
1480 
45.  Martin, J.; Samoilovich, E.; Dunn, G.; Lackenby, A.; Feldman, E.; Heath, A.; Svirchevskaya, E.; 
Cooper, G.; Yermalovich, M.; Minor, P.D. Isolation of an intertypic poliovirus capsid 
recombinant from a child with vaccine-associated paralytic poliomyelitis. J. Virol. 2002,  76, 
10921–10928. 
46.  Kyriakopoulou, Z.; Kottaridi, C.; Dedepsidis, E.; Bolanaki, E.; Levidiotou-Stefanou, S.; 
Markoulatos, P. Molecular characterization of wild-type polioviruses isolated in greece during the 
1996 outbreak in albania. J. Clin. Microbiol. 2006, 44, 1150–1152. 
47.  Mueller, J.E.; Bessaud, M.; Huang, Q.S.; Martinez, L.C.; Barril, P.A.; Morel, V.; Balanant, J.; 
Bocacao, J.; Hewitt, J.; Gessner, B.D.; Delpeyroux, F.; Nates, S.V. Environmental poliovirus 
surveillance during oral poliovirus vaccine and inactivated poliovirus vaccine use in cordoba 
province, argentina. Appl. Environ. Microbiol. 2009, 75, 1395–1401. 
48.  Zhang, Y.; Zhu, S.; Yan, D.; Liu, G.; Bai, R.; Wang, D.; Chen, L.; Zhu, H.; An, H.; Kew, O.; Xu, 
W. Natural type 3/type 2 intertypic vaccine-related poliovirus recombinants with the first 
crossover sites within the vp1 capsid coding region. PLoS One 2010, 5, e15300. 
49.  Terry, L. The Association of Cases of Poliomyelitis with the Use of Type 3 Oral Poliomyelitis 
Vaccines; US Department of Health, Education and Welfare: Washington D.C., USA, 1962. 
50.  Lipskaya, G.Y.; Muzychenko, A.R.; Kutitova, O.K.; Maslova, S.V.; Equestre, M.; Drozdov, S.G.; 
Bercoff, R.P.; Agol, V.I. Frequent isolation of intertypic poliovirus recombinants with serotype 2 
specificity from vaccine-associated polio cases. J. Med. Virol. 1991, 35, 290–296. 
51.  Furione, M.; Guillot, S.; Otelea,  D.; Balanant, J.; Candrea, A.; Crainic, R. Polioviruses with 
natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis. Virology 
1993, 196, 199–208. 
52.  Cherkasova, E.A.; Korotkova, E.A.; Yakovenko, M.L.; Ivanova, O.E.; Eremeeva, T.P.; 
Chumakov, K.M.; Agol, V.I. Long-term circulation of vaccine-derived poliovirus that causes 
paralytic disease. J. Virol. 2002, 76, 6791–6799. 
53.  Georgescu, M.M.; Delpeyroux, F.; Tardy-Panit, M.; Balanant, J.; Combiescu, M.; Combiescu, A.A.; 
Guillot, S.; Crainic, R. High diversity of poliovirus strains isolated from the central nervous system 
from patients with vaccine-associated paralytic poliomyelitis. J. Virol. 1994, 68, 8089–8101. 
54.  Guillot, S.; Caro, V.; Cuervo, N.; Korotkova, E.; Combiescu, M.; Persu, A.; Aubert-Combiescu, 
A.; Delpeyroux, F.; Crainic, R. Natural genetic exchanges between vaccine and wild poliovirus 
strains in humans. J. Virol. 2000, 74, 8434–8443. 
55.  Combiescu, M.; Guillot, S.; Persu, A.; Baicus, A.; Pitigoi, D.; Balanant, J.; Oprisan, G.; Crainic, 
R.; Delpeyroux, F.; Aubert-Combiescu, A. Circulation of a type 1 recombinant vaccine-derived 
poliovirus strain in a limited area in romania. Arch. Virol. 2007, 152, 727–738. 
56.  Baicus, A.; Persu, A.; Dinu, S.; Joffret, M.L.; Delpeyroux, F.; Oprisan, G. The frequency and 
biodiversity of poliovirus and non-polio enterovirus strains isolated from healthy children living 
in a limited area in romania. Arch. Virol. 2011, 156, 701–706. 
57.  Cuervo, N.S.; Guillot, S.; Romanenkova, N.; Combiescu, M.; Aubert-Combiescu, A.; Seghier, M.; 
Caro, V.; Crainic, R.; Delpeyroux, F. Genomic features of intertypic recombinant sabin poliovirus 
strains excreted by primary vaccinees. J. Virol. 2001, 75, 5740–5751. 
58.  Karakasiliotis, I.; Paximadi, E.; Markoulatos, P. Evolution of a rare vaccine-derived 
multirecombinant poliovirus. J. Gen. Virol. 2005, 86, 3137–3142. Viruses 2011, 3                         
 
 
1481 
59.  Georgopoulou, A.; Markoulatos, P. Sabin type 2 polioviruses with intertypic vaccine/vaccine 
recombinant genomes. Eur. J. Clin. Microbiol. Infect. Dis. 2001, 20, 792–799. 
60.  Dedepsidis, E.; Pliaka, V.; Kyriakopoulou, Z.; Brakoulias, C.; Levidiotou-Stefanou, S.; Pratti, A.; 
Mamuris, Z.; Markoulatos, P. Complete genomic characterization of an intertypic sabin 3/sabin 2 
capsid recombinant. FEMS Immunol. Med. Microbiol. 2008, 52, 343–351. 
61.  Georgescu, M.M.; Delpeyroux, F.; Crainic, R. Tripartite genome organization of a natural type 2 
vaccine/nonvaccine recombinant poliovirus. J. Gen. Virol. 1995, 76, 2343–2348. 
62.  Liu, H.M.; Zheng, D.P.; Zhang, L.B.; Oberste, M.S.; Kew, O.M.; Pallansch, M.A. Serial 
recombination during circulation of type 1 wild-vaccine recombinant polioviruses in china. 
J. Virol. 2003, 77, 10994–11005. 
63.  Zhang, Y.; Wang, H.; Zhu, S.; Li, Y.; Song, L.; Liu, Y.; Liu, G.; Nishimura, Y.; Chen, L.; Yan, 
D.; Wang, D.; An, H.; Shimizu, H.; Xu, A.; Xu, W. Characterization of a rare natural intertypic 
type 2/type 3 penta-recombinant vaccine-derived poliovirus isolated from a child with acute 
flaccid paralysis. J. Gen. Virol. 2010, 91, 421–429. 
64.  Gavrilin, G.V.; Cherkasova, E.A.; Lipskaya, G.Y.; Kew, O.M.; Agol, V.I. Evolution of circulating 
wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: A unifying 
model. J. Virol. 2000, 74, 7381–7390. 
65.  Martin, J.; Dunn, G.; Hull, R.; Patel, V.; Minor, P.D. Evolution of the sabin strain of type 3 
poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. 
J. Virol. 2000, 74, 3001–3010. 
66.  Yang, C.F.; Chen, H.Y.; Jorba, J.; Sun, H.C.; Yang, S.J.; Lee, H.C.; Huang, Y.C.; Lin, T.Y.; 
Chen, P.J.; Shimizu, H.; et al. Intratypic recombination among lineages of type 1 vaccine-derived 
poliovirus emerging during chronic infection of an immunodeficient patient. J. Virol. 2005, 79, 
12623–12634. 
67.  Yang, C.F.; Naguib, T.; Yang, S.J.; Nasr, E.; Jorba, J.; Ahmed, N.; Campagnoli, R.; van der Avoort, 
H.; Shimizu, H.; Yoneyama, T.; et al. Circulation of endemic type 2 vaccine-derived poliovirus in 
egypt from 1983 to 1993. J. Virol. 2003, 77, 8366–8377. 
68.  Blomqvist, S.; Savolainen, C.; Laine, P.; Hirttio, P.; Lamminsalo, E.; Penttila, E.; Joks, S.; 
Roivainen, M.; Hovi, T. Characterization of a highly evolved vaccine-derived poliovirus type 3 
isolated from sewage in estonia. J. Virol. 2004, 78, 4876–4883. 
69.  Alexander, J.P., Jr.; Gary, H.E., Jr.; Pallansch, M.A. Duration of poliovirus excretion and its 
implications for acute flaccid paralysis surveillance: A review of the literature. J. Infect. Dis. 
1997, 175, S176–S182. 
70.  Wassilak, S.; Pate, M.A.; Wannemuehler, K.; Jenks, J.; Burns, C.; Chenoweth, P.; Abanida, E.A.; 
Adu, F.; Baba, M.; Gasasira, A.; et al. Outbreak of type 2 vaccine-derived poliovirus in nigeria: 
Emergence and widespread circulation in an underimmunized population. J. Infect. Dis. 2011, 
203, 898–909. 
71.  MacLennan, C.; Dunn, G.; Huissoon, A.P.; Kumararatne, D.S.; Martin, J.; O'Leary, P.; 
Thompson, R.A.; Osman, H.; Wood, P.; Minor, P.; et al. Failure to clear persistent vaccine-derived 
neurovirulent poliovirus infection in an immunodeficient man. Lancet 2004, 363, 1509–1513. Viruses 2011, 3                         
 
 
1482 
72.  Kew, O.M.; Sutter, R.W.; Nottay, B.K.; McDonough, M.J.; Prevots, D.R.; Quick, L.; Pallansch, 
M.A. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. 
J. Clin. Microbiol. 1998, 36, 2893–2899. 
73.  Yoneyama, T.; Sakae, K.; Baba, J.; Nakayama, T.; Chijiwa, K.; Kizoe, K.; Shimizu, H.; Iizuka, 
S.; Ishizaki, T.; Kondo, R.; Miyamura, T. Surveillance of poliovirus-isolates in Japan, 2000. 
Jpn. J. Infect. Dis. 2001, 54, 80–82. 
74.  Odoom, J.K.; Yunus, Z.; Dunn, G.; Minor, P.D.; Martin, J. Changes in population dynamics 
during long-term evolution of sabin type 1 poliovirus in an immunodeficient patient. J. Virol. 
2008, 82, 9179–9190. 
75.  Horie, H.; Yoshida, H.; Matsuura, K.; Miyazawa, M.; Wakabayashi, K.; Nomoto, A.; Hashizume, 
S. Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild 
strain mahoney from sewage in japan. J. Med. Virol. 2002, 68, 445–451. 
76.  Pavlov, D.N.; Van Zyl, W.B.; Van Heerden, J.; Grabow, W.O.; Ehlers, M.M. Prevalence of vaccine-
derived polioviruses in sewage and river water in South Africa. Water. Res. 2005, 39, 3309–3319. 
77.  Roivainen, M.; Blomqvist, S.; Al-Hello, H.; Paananen, A.; Delpeyroux, F.; Kuusi, M.; Hovi, T. 
Highly divergent neurovirulent vaccine-derived polioviruses of all three serotypes are recurrently 
detected in finnish sewage. Euro. Surveill. 2010, 15, pii: 19566. 
78.  Cernakova, B.; Sobotova, Z.; Rovny, I.; Blahova, S.; Roivainen, M.; Hovi, T. Isolation of vaccine-
derived polioviruses in the slovak republic. Eur. J. Clin. Microbiol. Infect. Dis. 2005, 24, 438–439. 
79.  Shulman, L.M.; Manor, Y.; Handsher, R.; Delpeyroux, F.; McDonough, M.J.; Halmut, T.; 
Silberstein, I.; Alfandari, J.; Quay, J.; Fisher, T.; et al. Molecular and antigenic characterization of 
a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in israel. 
J. Clin. Microbiol. 2000, 38, 3729–3734. 
80.  Shulman, L.M.; Manor, Y.; Sofer, D.; Handsher, R.; Swartz, T.; Delpeyroux, F.; Mendelson, E. 
Neurovirulent vaccine-derived polioviruses in sewage from highly immune populations. 
PLoS One 2006, 1, e69. 
81.  Martin, J. Vaccine-derived poliovirus from long term excretors and the end game of polio 
eradication. Biologicals 2006, 34, 117–122. 
82.  Buttinelli, G.; Donati, V.; Fiore, S.; Marturano, J.; Plebani, A.; Balestri, P.; Soresina, A.R.; 
Vivarelli, R.; Delpeyroux, F.; Martin, J.; Fiore, L. Nucleotide variation in sabin type 2 poliovirus 
from an immunodeficient patient with poliomyelitis. J. Gen. Virol. 2003, 84, 1215–1221. 
83.  Kew, O.; Morris-Glasgow, V.; Landaverde, M.; Burns, C.; Shaw, J.; Garib, Z.; Andre, J.; 
Blackman, E.; Freeman, C.J.; Jorba, J.; et al. Outbreak of poliomyelitis in hispaniola associated 
with circulating type 1 vaccine-derived poliovirus. Science 2002, 296, 356–359. 
84.  Shimizu, H.; Thorley, B.; Paladin, F.J.; Brussen, K.A.; Stambos, V.; Yuen, L.; Utama, A.; Tano, 
Y.; Arita, M.; Yoshida, H.; et al. Circulation of type 1 vaccine-derived poliovirus in the 
philippines in 2001. J. Virol. 2004, 78, 13512–13521. 
85.  Adu, F.; Iber, J.; Bukbuk, D.; Gumede, N.; Yang, S.J.; Jorba, J.; Campagnoli, R.; Sule, W.F.; 
Yang, C.F.; Burns, C.; et al. Isolation of recombinant type 2 vaccine-derived poliovirus (vdpv) 
from a nigerian child. Virus. Res. 2007, 127, 17–25. 
86.  Acute flaccid paralysis associated with circulating vaccine-derived poliovirus, philippines, 2001. 
Wkly. Epidemiol. Rec. 2001, 76, 319–320. Viruses 2011, 3                         
 
 
1483 
87.  Rousset, D.; Rakoto-Andrianarivelo, M.; Razafindratsimandresy, R.;  Randriamanalina, B.; 
Guillot, S.; Balanant, J.; Mauclere, P.; Delpeyroux, F. Recombinant vaccine-derived poliovirus in 
madagascar. Emerg. Infect. Dis. 2003, 9, 885–887. 
88.  Rakoto-Andrianarivelo, M.; Guillot, S.; Iber, J.; Balanant, J.; Blondel, B.; Riquet, F.; Martin, J.; 
Kew, O.; Randriamanalina, B.; Razafinimpiasa, L.; et al. Co-circulation and evolution of 
polioviruses and species c enteroviruses in a district of madagascar. PLoS. Pathog. 2007, 3, e191. 
89.  Rakoto-Andrianarivelo, M.; Gumede, N.; Jegouic, S.; Balanant, J.; Andriamamonjy, S.N.; 
Rabemanantsoa, S.; Birmingham, M.; Randriamanalina, B.; Nkolomoni, L.; Venter, M.; et al. 
Reemergence of recombinant vaccine-derived poliovirus outbreak in madagascar. J. Infect. Dis. 
2008, 197, 1427–1435. 
90.  Joffret M.L.; Jegouic S.; Bessaud M.; Balanant J; Tran C.; Caro V.; Holmblat B.; 
Razafindratsimandresy R.; Reynes J-M.; Rakoto-Andrianarivelo M.; et al. Common and diverse 
features of co-circulating type 2 and 3 recombinant vaccine-derived polioviruses isolated from 
patients with poliomyelitis and from healthy children. J. Infect. Dis. 2011, in press. 
91.  Jenkins, H.E.; Aylward, R.B.; Gasasira, A.; Donnelly, C.A.; Mwanza, M.; Corander, J.; Garnier, 
S.; Chauvin, C.; Abanida, E.; Pate, M.A.; Adu, F.; Baba, M.; Grassly, N.C. Implications of a 
circulating vaccine-derived poliovirus in nigeria. N. Engl. J. Med. 2010, 362, 2360–2369. 
92.  CDC. Progress toward poliomyelitis eradication—Nigeria, January 2009–June 2010.  MMWR. 
Morb. Mortal. Wkly. Rep. 2010, 59, 802–807. 
93.  Global update on vaccine-derived polioviruses, January 2006–August 2007. Wkly. Epidemiol. 
Rec. 2007, 82, 337–343. 
94.  Arita, M.; Zhu, S.L.; Yoshida, H.; Yoneyama, T.; Miyamura, T.; Shimizu, H. A sabin 3-derived 
poliovirus recombinant contained a sequence homologous with indigenous human enterovirus 
species c in the viral polymerase coding region. J. Virol. 2005, 79, 12650–12657. 
95.  Burns, C. Centre for diseases control and prevention, Atlanta, Georgia. Personnal communication. 
2011. 
96.  Estivariz, C.F.; Watkins, M.A.; Handoko, D.; Rusipah, R.; Deshpande, J.; Rana, B.J.; Irawan, E.; 
Widhiastuti, D.; Pallansch, M.A.; Thapa, A.; et al. A large vaccine-derived poliovirus outbreak on 
Madura Island—Indonesia, 2005. J. Infect. Dis. 2008, 197, 347–354. 
97.  Deshpande, J. Enterovirus Research Centre, Mumbai, India. Personnal communication, 2011. 
98.  Liang, X.; Zhang, Y.; Xu, W.; Wen, N.; Zuo, S.; Lee, L.A.; Yu, J. An outbreak of poliomyelitis 
caused by type 1 vaccine-derived poliovirus in china. J. Infect. Dis. 2006, 194, 545–551. 
99.  Alexander, J.P.; Ehresmann, K.; Seward, J.; Wax, G.; Harriman, K.; Fuller, S.; Cebelinski, E.A.; 
Chen, Q.; Jorba, J.; Kew, O.M.; et al. Transmission of imported vaccine-derived poliovirus in an 
undervaccinated community in minnesota. J. Infect. Dis. 2009, 199, 391–397. 
100. Romanenkova, N.I.; Guillot, S.; Rozaeva, N.R.; Crainic, R.; Bichurina, M.A.; Delpeyroux, F. Use 
of a multiple restriction fragment length polymorphism method for detecting vaccine-derived 
polioviruses in clinical samples. J. Clin. Microbiol. 2006, 44, 4077–4084. 
101. Korotkova, E.A.; Park, R.; Cherkasova, E.A.; Lipskaya, G.Y.; Chumakov, K.M.; Feldman, E.V.; 
Kew, O.M.; Agol, V.I. Retrospective analysis of a local cessation of vaccination against 
poliomyelitis: A possible scenario for the future. J. Virol. 2003, 77, 12460–12465. Viruses 2011, 3                         
 
 
1484 
102. Bouchard, M.J.; Lam, D.H.; Racaniello, V.R. Determinants of attenuation and temperature 
sensitivity in the type 1 poliovirus sabin vaccine. J. Virol. 1995, 69, 4972–4978. 
103. Oberste, M.S.; Maher, K.; Kilpatrick, D.R.; Flemister, M.R.; Brown, B.A.; Pallansch, M.A. Typing 
of human enteroviruses by partial sequencing of vp1. J. Clin. Microbiol. 1999, 37, 1288–1293. 
104. Caro, V.; Guillot, S.; Delpeyroux, F.; Crainic, R. Molecular strategy for 'serotyping' of human 
enteroviruses. J. Gen. Virol. 2001, 82, 79–91. 
105. Brown, B.; Oberste, M.S.; Maher, K.; Pallansch, M.A. Complete genomic sequencing shows that 
polioviruses and members of human enterovirus species c are closely related in the noncapsid 
coding region. J. Virol. 2003, 77, 8973–8984. 
106. WHO. Vaccine-derived polioviruses—Update. Wkly. Epidemiol. Rec. 2006, 81, 398–404. 
107. Rakoto-Andrianarivelo, M.; Rousset, D.; Razafindratsimandresy, R.; Chevaliez, S.; Guillot, S.; 
Balanant, J.; Delpeyroux, F. High frequency of human enterovirus species c circulation in 
madagascar. J. Clin. Microbiol. 2005, 43, 242–249. 
108. Bessaud, M.; Joffret, M.L.; Holmblat, B.; Razafindratsimandresy R.; Delpeyroux,  F. Genetic 
relationship between cocirculating human enteroviruses species c. PLoS One 2011, submitted for 
publication. 
109. Melnick, J.L. Enterovirus: Polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In 
Fields Virology, 5th ed.; Knipe, D.M., Howley, P.M., Griffin, D.E., Lamb, R.A., Martin, M.A. EdS.; 
Wolters Kluwer Health/Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2007; Volume 1. 
110. Nathanson, N.; Kew, O.M. From emergence to eradication: The epidemiology of poliomyelitis 
deconstructed. Am. J. Epidemiol. 2010, 172, 1213–1229. 
111. Jiang, P.; Faase, J.A.; Toyoda, H.; Paul, A.; Wimmer, E.; Gorbalenya, A.E. Evidence for 
emergence of diverse polioviruses from c-cluster coxsackie a viruses and implications for global 
poliovirus eradication. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 9457–9462. 
112. Liu, Y.; Wang, C.; Mueller, S.; Paul, A.V.; Wimmer, E.; Jiang, P. Direct interaction between two 
viral proteins, the nonstructural protein 2c and the capsid protein vp3, is required for enterovirus 
morphogenesis. PLoS. Pathog. 2010, 6, e1001066. 
113. Riquet, F.B.; Blanchard, C.; Jegouic, S.; Balanant, J.; Guillot, S.; Vibet, M.A.; Rakoto-
Andrianarivelo, M.; Delpeyroux, F. Impact of exogenous sequences on the characteristics of an 
epidemic type 2 recombinant vaccine-derived poliovirus. J. Virol. 2008, 82, 8927–8932. 
114. Jegouic, S.; Joffret, M.L.; Blanchard, C.; Riquet, F.B.; Perret, C.; Pelletier, I.; Colbère-Garapin, 
F.; Rakoto-Andrianarivelo, M.; Delpeyroux, F. Recombination between polioviruses and co-
circulating coxsackie a viruses: Role in the emergence of pathogenic vaccine-derived 
polioviruses. PLoS. Pathog. 2009, 5, e1000412. 
115. Dahourou, G.; Guillot, S.; Le Gall, O.; Crainic, R. Genetic recombination in wild-type poliovirus. 
J. Gen. Virol. 2002, 83, 3103–3110. 
© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 